SUCCESSFUL TREATMENT WITH ADALIMUMAB IN INFLIXIMAB‐RESISTANT CROHN's DISEASE

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

“…The literature search revealed 797 references in Pubmed and 1067 in Embase; however, some references were excluded, among other reasons, for duplication and non‐availability of data on the effectiveness of the second anti‐TNF . Finally, only 46 studies met the inclusion criteria and were included . Of these, 37 focused on CD (Tables S1 and S2), 8 on UC, and 1 on pouchitis (Table S3).…”

“…Studies were classified by type of IBD in order to pool data and perform the statistical meta‐analysis; therefore, the pouchitis study was excluded from the meta‐analysis. Of the CD studies, 32 evaluated switching from IFX to ADA, 4 switching from IFX to CZP, and 1 switching from ADA to IFX . All UC studies evaluated switching from IFX to ADA.…”

A systematic review of dropout from treatment in outpatients with anorexia nervosa

“…Adalimumab reduced the risk of CD‐related hospitalization and surgeries39 and induced rapid and complete fistula closure that was sustained for up to 2 years 11, 40. Adalimumab also induces and maintains remission in adult patients with moderate to severe CD who could not tolerate or who lost response to infliximab therapy 8, 41–45. These benefits are coupled with low incidences of malignancy, lymphoma, opportunistic infection (including tuberculosis), demyelinating disorders, congestive heart failure, and lupus‐related disorders.…”

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis

“…Recently, clinical trials have demonstrated that adalimumab is effective and safe to use in patients who lose response to infliximab 6–11 . Adalimumab is a subcutaneously administered human anti‐TNFα monoclonal antibody.…”